Papers, abstracts, presentations, posters and webcasts emanating from the audit
Webcast of an ePoster presentation of the results from the ABCD nationwide SGLT2i audits presented by ABCD audits research fellow, Dr Thomas Crabtree at EASD 2021:
Sodium-glucose linked transporter 2 inhibitors (SGLT2s) and alanine aminotransferase levels (ALT) in the Associated of British Clinical Diabetologists (ABCD) audits - Virtual Meeting | EASD
Webcast of an ePoster presentation of the results from the ABCD nationwide SGLT2i audits presented by ABCD research fellow Dr Thomas Crabtree at DUK Professional Conference 2021
Comparing the effects of different-sodium glucose link-transporter 2-inhibitors (SGLT2i) on HbA1c an weight in the real world: updated analysis from the Association of British Clinical Diabetologists (ABCD) Audit Programmes
Webcast of an ePoster presentation of the results from the ABCD nationwide SGLT2i audits presented by ABCD research fellow Dr Thomas Crabtree at DUK Professional Conference 2021
The impact of sodium glucose link transporter-2 inhibitors [SGLT2i] on Fib4 score in patients with type 2 diabetes: Analysis using Association of British Clinical Diabetologists [ABCD] nationwide audit data
Webcast of ABCD research fellow Dr Mahender Yadagiri presenting ABCD dapagliflozin audit poster at EASD, Munich, 13 September 2016
Effect of dapagliflozin on HbA1c and weight after its addition to various combinations of other diabetes medications
Webcast by Dr Harshal Deshmukh from Hull, UK, made at the American Diabetes Association virtual meeting in June 2020 reporting data from the ABCD nationwide audits of SGLT2 inhibitors in real clinical use in the UK
Effect Of Raised Alanine Transaminase (ALT) On HbA1c Response to SGLT2 Inhibitors In Type 2 Diabetes
Ken Yan Thong, Mahender Yadagiri, Dennis Joseph Barnes, David Stuart Morris, Tahseen Ahmad Chowdhury, Ling Ling Chuah, Anthony Michael Robinson, Stephen Charles Bain, Karen Ann Adamson, Robert Elford John Ryder, ABCD Nationwide Dapagliflozin Audit contributors: Clinical risk factors predicting genital fungal infections with sodium–glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit
Primary Care Diabetes pcd.2017.06.004
Full paper (ABCD members and audit contributors only):
Primary Care Diabetes pcd.2017.06.004
All contributors are listed
Thomas SJ Crabtree, Mahender Yadagiri, Ian Gallen, Suzanne Phillips, Alison Evans, Anurita Rohilla, Devesh Sennik, Alex Bickerton, Susannah Rowles, Iskandar Idris, Robert E J Ryder, On behalf of the ABCD dapagliflozin audit contributors. The effect of dapagliflozin on alanine aminotransferase as a marker of liver inflammation: updated results from the ABCD dapagliflozin audit
Abstract Br J Diabetes 2020; 20:19-24
Full Paper Br J Diabetes 2020; 20: 19-24
All contributors are listed
Crabtree TSJ, Bickerton A, Dhatariya K, Gallagher A, Elliott J, Adamson K, Gallen I, Barnes D, Sivappriyan S, Idris I, Ryder REJ, All SGLT2i Audit Contributors. Real-world cross-comparison of metabolic outcomes with different sodium-glucose co-transporter 2 inhibitors agents in adults with type 2 diabetes: results from the Association of British Clinical Diabetologists audit programme
Abstract Br J Diabetes 2024;24(1):51-55
Full Text Br J Diabetes 2024;24(1):51-55
All contributors are listed
ABCD Autumn meeting, London, November 6 2015
DUK Professional Conference, Glasgow, March 4 2016
ADA, San Diego, June 11 2017
DUK Professional Conference, Virtual March 2021
EASD 2022 SGLT2 Slides
ABCD Autumn Meeting, London, 2015a: M Yadagiri, P Sen Gupta, ML Cull, R Peter, P De, A Robinson, KA Adamson, REJ Ryder on behalf of the ABCD nationwide dapagliflozin audit contributors. HbA1c, weight, body mass index (BMI) and systolic blood pressure changes in the ABCD nationwide dapagliflozin audit. Oral presentation: Abstract 2
ABCD Autumn Meeting, London, 2015b: M Yadagiri, P Sen Gupta, SC Bain, A Robinson, M Phyactou, A Kennedy, KA Adamson, REJ Ryder on behalf of the ABCD nationwide dapagliflozin audit contributors. Does dapagliflozin affect the metabolic response in patients with elevated alanine aminotransferase and Type 2 diabetes?: the Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit. Poster presentation: Abstract 10. Diabetes 2016 Jul; 65 (Supplement 1): 1123-P
DUK, Glasgow, 2016a: – M Yadagiri, P Sen Gupta, ML Cull, J Eyles, A Robinson, L Oguntolu, K Imtiaz, K Adamson, REJ Ryder and the ABCD Nationwide Dapagliflozin Audit Contributors. HbA1c,weight,body mass index(BMI) and systolic blood pressure changes in the ABCD nationwide audit(poster presentation:P432). Diabetes 2016 Jul; 65 (Supplement 1): 1164-P
DUK, Glasgow, 2016b: – M Yadagiri, P Sen Gupta, JW Stephens, A Robinson, M Phylactou, A Kennedy, J Clark, J Wilding, KA Adamson, REJ Ryder and the ABCD Nationwide Dapagliflozin Audit Contributors. Does dapagliflozin affect the metabolic response in patients with elevated alanine aminotransferase and Type 2 diabetes? The Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit(oral presentation:A73/P427). Diabetic Medicine 2016. 33 (Suppl 1): Abstract A73.
ABCD Spring Meeting 2016, Manchester: - K.Y. Thong, M. Yadagiri, P. Sen Gupta, P. Winocour, M. Joshi, J. Wilding, JW Stephens, SC Bain, A. Robinson, IW Gallen, KA Adamson, REJ Ryder and the ABCD Nationwide Dapagliflozin audit contributors. The glycaemic response to dapagliflozin according to intensity of background diabetes treatment or duration of Type 2 Diabetes: the Association of British Clinical Diabetologists Nationwide Dapagliflozin audit. Poster presentation : Abstract 3. Diabetes 2016 Jul; 65 (Supplement 1): 1170-P
ADA New Orleans, 2016a - M. Yadagiri, P. Sen Gupta, ML Cull, D. Price, V Oguntolu, K Imtiaz, D Barnes, A Nugent, A Robinson, IW Gallen, KA Adamson, REJ Ryder and the ABCD Nationwide Dapagliflozin audit contributors. Does dapagliflozin affect the metabolic response in patients with elevated alanine aminotransferase (ALT) and Type 2 diabetes? The Association of British Diabetologists Nationwide Dapagliflozin audit. Poster presentation: 1123-P
ADA New Orleans, 2016b – M. Yadagiri, P. Sen Gupta, A. Kennedy, T. Pang, J. Clark, H. Pathan, P.C. Johnston, R. Chudleigh, A. Robinson, IW Gallen, KA Adamson, REJ Ryder and the ABCD Nationwide Dapagliflozin audit contributors. HbA1c,weight, body mass index(BMI) and systolic blood pressure response to dapagliflozin: The Association of British Clinical Diabetologists Nationwide Dapagliflozin audit. Poster presentation: 1164-P
ADA New Orleans, 2016c - K.Y. Thong, M. Yadagiri, P. Sen Gupta, P. Winocour, M. Joshi, J. Wilding, JW Stephens, SC Bain, A. Robinson, IW Gallen, KA Adamson, REJ Ryder and the ABCD Nationwide Dapagliflozin audit contributors. The glycaemic response to dapagliflozin according to intensity of background diabetes treatment or duration of Type 2 Diabetes: the Association of British Clinical Diabetologists Nationwide Dapagliflozin audit. Poster presentation: 1170-P
EASD Munich, 2016 - M Yadagiri, P Sen Gupta, T Pang, L Balmuri, T Robinson, S Bain, IW Gallen, KA Adamson, REJ Ryder on behalf of ABCD nationwide dapagliflozin audit contributors. Effect of dapagliflozin on HbA1c and weight after its addition to various combinations of other diabetes medications: Association of British Clinical Diabetologists(ABCD) nationwide dapagliflozin audit –Diabetologia(2016) Vol 59 Supplement 1: S581- Abstract 712.
DUK Manchester, 2017 - M Yadagiri, P Sen Gupta, A Kennedy, T Pang, L Balmuri, T Robinson, S Bain, IW Gallen, KA Adamson, REJ Ryder on behalf of ABCD nationwide dapagliflozin audit contributors. The effect of dapagliflozin on HbA1c and weight after its addition to commonly prescribed dual combination diabetes medication regimes in people with Type 2 diabetes in a real-world UK setting: the Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit – Diabetic Medicine volume 34 (Supplement S1, 36-194) - Poster 519
ADA San Diego, 2017a - M Yadagiri, S C Bain, T Robinson, JPH Wilding, T Pang, B McGowan, P Winocour, V Oguntolu, J Clark, H Partridge, IW Gallen, KA Adamson, REJ Ryder, ABCD nationwide dapagliflozin audit contributors. Dapagliflozin in Renal Impairment : the Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit – Diabetes June 2017 Volume 66 (Supplement 1, A45) : Oral 172-OR
ADA San Diego,2017b - KY Thong, M Yadagiri, P Tong, D Barnes, D Morris, T Chowdhury, LL Chuah, M Cohen, A Kennedy, T Robinson, SC Bain, KA Adamson, REJ Ryder and the ABCD Nationwide Dapagliflozin audit contributors. Lack of risk factors predicting the development of genital mycotic infections among patients treated with dapagliflozin : the Association of British Clinical Diabetologists Nationwide Dapagliflozin audit. Poster presentation: 1287-P
ADA Virtual Meeting, 2020 - Harshal Deshmukh, Alex Bickerton, Suzanne M. Phillips, Alison Evans, Rajeev P. Raghavan, Devesh K. Sennik, Anurita Rohilla, Karen Adamson, Mahender Yadagiri, Ian W. Gallen, Robert E. Ryder and Thozhukat Sathyapalan. Effect of Raised Alanine Transaminase (ALT) Levels on HbA1c in the Association of British Clinical Diabetologists (ABCD) Nationwide Audits of SGLT2 Inhibitors (SGLT2i) - Diabetes 2020 Jun; 69(Supplement 1):1110-P
DUK London TC1, 2021 Crabtree, T. S. J., J. Elliott, S. Sivappriyan, D. Barnes, A. Bickerton, I. Gallen, I. Idris, and R. E. J. Ryder. "The impact of sodium glucose link transporter-2 inhibitors (SGLT2i) on Fib4 score in patients with type 2 diabetes: Analysis using Association of British Clinical Diabetologists (ABCD) nationwide audit data." In DIABETIC MEDICINE, vol. 38. 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY, 2021.
DUK London TC2, 2021 Crabtree, T. S. J., K. Dhatariya, A. Bickerton, S. Sivappriyan, D. Barnes, S. Tarpey, S. Rowles, K. Adamson, I. Gallen, and R. E. J. Ryder. "Comparing the effects of different sodium-glucose link transporter 2 inhibitors (SGLTi) on HbA1c and weight in the real world: updated analysis from the Association of British Clinical Diabetologists (ABCD) audit programmes." In DIABETIC MEDICINE, vol. 38. 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY, 2021.
EASD Virtual Meeting, 2021 Gallen, I., T. S. J. Crabtree, A. Gallagher, K. Dhatariya, A. Bickerton, J. Elliott, G. Rayman, and R. E. J. Ryder. "Sodium-glucose linked transporter 2 inhibitors (SGLT2s) and alanine aminotransferase levels (ALT) in the Associated of British Clinical Diabetologists (ABCD) audits." In DIABETOLOGIA, vol. 64, no. SUPPL 1, pp. 218-218. ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES: SPRINGER, 2021.
ADA New Orleans, 2022 Thomas S.J. Crabtree, Alison Gallagher, Siva Sivappriyan, Ketan Dhatariya, Rajeev P. Raghavan, Alex Bickerton, Jackie Elliott, Melissa L. Cull, Gerry Rayman, Ian W. Gallen, Iskandar R. Idris, Robert E. Ryder; 858-P: Predictors of HbA1c and Weight Response to Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i) in the Association of British Clinical Diabetologist (ABCD) UK Nationwide Audit. Diabetes 1 June 2022; 71 (Supplement_1): 858–P. https://doi.org/10.2337/db22-858-P
DUK 2022 T. S. J. Crabtree, A. Gallagher, I. Gallen, A. Melvin, J. Elliott, A. Bickerton, K. Dhatariya, G. Rayman, R. E. J. Ryder. The effect of sodium-glucose link transporter 2 inhibitors (SGLT2i) on microalbuminuria: Cross-class analysis from the ABCD audit programme. Diabetic Medicine, Volume 39, Issue S1: A41 (P230). https://doi.org/10.1111/dme.14810
Oral Abstract: https://onlinelibrary.wiley.com/doi/10.1111/dme.14809
Poster Abstract: https://onlinelibrary.wiley.com/doi/10.1111/dme.14810
ABCD London, Autumn 2015
DUK Professional Conference, Glasgow, March 4 2016a
DUK Professional Conference, Glasgow, March 4 2016b
ABCD Manchester, Spring 2016
ADA New Orleans, June 2016a
ADA New Orleans, June 2016b
ADA New Orleans, June 2016c
EASD Munich, 2016
DUK Professional Conference, Manchester, March 2017
ADA San Diego, June 11 2017b
ADA Virtual Meeting, June 2020HD
Diabetes UK Professional Conference 2021TC
Diabetes UK Professional Conference 2021TC2
Diabetes UK Professional Conference 2022
ADA June 2022
The ABCD nationwide dapagliflozin audit is an independent audit supported by an unrestricted grant from Astra Zeneca
